AstraZeneca stock dives 9% after heart drug trial misses target
—·2h
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.
ChannelsstocksCountriesusaCategoriespharma
Open original source ↗Published
7/9/2026, 8:53:44 AM
Fetched
7/9/2026, 9:07:48 AM
Confidence
60 / 100
Relevance
35 / 100
Trust
—
Language
en